Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction

Wallis, Robert S.; Broder, Michael S.; Wong, Jeffrey; Beenhouwer, David O.

doi:10.1086/424455

Cited by 203 publications

(156 citation statements)

References 1 publication

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…However, a possible difference between infliximab and etanercept in the incidence of TB is suspected from the spontaneous reporting of TB cases to the US Food and Drug Administration (FDA) (5) before September 2002, when no recommendations for screening for latent TB existed. In one study, the incidence of TB was 28 per 100,000 patient-years for patients receiving etanercept versus 54 per 100,000 patient-years for patients receiving infliximab (9). Likewise, 4 registries showed small differences (that were not statistically significant) in the incidence of TB between patients with RA receiving infliximab and those receiving etanercept; perhaps because in each of these registries the number of TB cases was low (n ϭ 2-13), these registries were not powered enough to demonstrate very rare events or to determine a difference in risk depending on the anti-TNF agent (1,2,6,7).…”

mentioning

confidence: 99%

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Tubach

Salmon

Ravaud

et al. 2009

Arthritis & Rheumatism

576

366

View full text Add to dashboard Cite

Objective. Tuberculosis (TB) is associated with anti-tumor necrosis factor (anti-TNF) monoclonal antibody (mAb) therapy, but whether this association is drug-specific remains a concern. Our objective was to describe cases of TB associated with anti-TNF mAb therapy, identify risk factors, and estimate the incidence.Methods. We conducted an incidence study and a case-control analysis to investigate the risk of newly diagnosed TB associated with the use of anti-TNF agents. As part of the French Research Axed on Tolerance of Biotherapies (RATIO) registry, for 3 years we collected cases of TB among French patients receiving anti-TNF mAb therapy for any indication; for each case, 2 patients treated with anti-TNF agents served as control subjects.Results. We collected 69 cases of TB in patients treated for rheumatoid arthritis (n ‫؍‬ 40), spondylarthritides (n ‫؍‬ 18), inflammatory colitis (n ‫؍‬ 9), psoriasis (n ‫؍‬ 1) and Behçet's disease (n ‫؍‬ 1) with infliximab (n ‫؍‬ 36), adalimumab (n ‫؍‬ 28), and etanercept (n ‫؍‬ 5). None of the patients had received correct chemoprophylactic treatment. The sex-and ageadjusted incidence rate of TB was 116.7 per 100,000 patient-years. The standardized incidence ratio (

show abstract

mentioning

confidence: 99%

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Tubach

Salmon

Ravaud

et al. 2009

Arthritis & Rheumatism

576

366

View full text Add to dashboard Cite

show abstract

“…En pacientes que reciben bloqueadores de FNTα se han descrito también infecciones por otros dos agentes intracelulares: L. monocytogenes y especies zoonóticas del género Salmonella 3,58,[60][61][62] . El cuadro clínico dominante en el caso de listeriosis corresponde a infecciones del SNC, las que tienen una alta letalidad 60 .…”

Section: Infecciones Asociadas Al Uso De Antagonistas Del Factor De Nunclassified

“…La incidencia de TBC puede alcanzar cifras muy elevadas en países con tasas endé-micas como España con valores superiores a 400 casos por 100.000 pacientes-año en ausencia de programas de prevención 63 . Los cuadros de TBC incluyen formas diseminadas o extrapulmonares 62 .…”

Section: Infecciones Asociadas Al Uso De Antagonistas Del Factor De Nunclassified

“…Las zonas de riesgo corresponden a regiones húmedas tropicales o subtropicales y la tasa en expuestos a infliximab es cercana a los 19 casos por 100.000 pacientes-año 62 . El riesgo parece muy inferior en los usuarios de etarnecept (3 por 100.000 pacientes-año).…”

Section: Infecciones Asociadas Al Uso De Antagonistas Del Factor De Nunclassified

“…La tasa de coccidiodimicosis en pacientes sometidos a bloqueadores del FNTα es aproximadamente 6 por 100.000 pacientes-año, notoriamente inferior a lo observado con TBC y principalmente asociado a infliximab 62,65 . Al igual que en el caso de histoplasmosis, este riesgo se manifiesta como neumonía o enfermedad diseminada con fiebre, tos y decaimiento 65 .…”

Section: Infecciones Asociadas Al Uso De Antagonistas Del Factor De Nunclassified

See 2 more Smart Citations

Infecciones en pacientes reumatológicos asociadas a corticosteroides y antagonistas del factor de necrosis tumoral α

Fíca

2014

Rev. chil. infectol.

View full text Add to dashboard Cite

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

Strangfeld

Listing²,

Herzer³

et al. 2009

JAMA

509

364

View full text Add to dashboard Cite

Context The risk of bacterial infection is increased in patients treated with drugs that inhibit tumor necrosis factor ␣ (TNF-␣). Little is known about the reactivation of latent viral infections during treatment with TNF-␣ inhibitors. Objective To investigate whether TNF-␣ inhibitors together as a class, or separately as either monoclonal anti-TNF-␣ antibodies (adalimumab, infliximab) or a fusion protein (etanercept), are related to higher rates of herpes zoster in patients with rheumatoid arthritis. Design, Setting, and Patients Patients were enrolled in the German biologics register RABBIT, a prospective cohort, between May 2001 and December 2006 at the initiation of treatment with infliximab, etanercept, adalimumab, or anakinra, or when they changed conventional disease-modifying antirheumatic drug (DMARD). Treatment, clinical status, and adverse events were assessed by rheumatologists at fixed points during follow-up. Main Outcome Measures Hazard ratio (HR) of herpes zoster episodes following anti-TNF-␣ treatment. Study aims were to detect a clinically significant difference (HR, 2.0) between TNF-␣ inhibitors as a class compared with DMARDs and to detect an HR of at least 2.5 for each of 2 types of TNF-␣ inhibitors, the monoclonal antibodies or the fusion protein, compared with conventional DMARDs. Results Among 5040 patients receiving TNF-␣ inhibitors or conventional DMARDs, 86 episodes of herpes zoster occurred in 82 patients. Thirty-nine occurrences could be attributed to treatment with anti-TNF-␣ antibodies, 23 to etanercept, and 24 to conventional DMARDs. The crude incidence rate per 1000 patient-years was 11.1 (95% confidence interval [CI], 7.9-15.1) for the monoclonal antibodies, 8.9 (95% CI, 5.6-13.3) for etanercept, and 5.6 (95% CI, 3.6-8.3) for conventional DMARDs. Adjusted for age, rheumatoid arthritis severity, and glucocorticoid use, a significantly increased risk was observed for treatment with the monoclonal antibodies (HR, 1.82 [95% CI, 1.05-3.15]), although this risk was lower than the threshold for clinical significance. No significant associations were found for etanercept use (HR, 1.36 [95% CI, 0.73-2.55]) or for anti-TNF-␣ treatment (HR, 1.63 [95% CI, 0.97-2.74]) as a class. Conclusion Treatment with monoclonal anti-TNF-␣ antibodies may be associated with increased risk of herpes zoster, but this requires further study.

show abstract

Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction

Cited by 203 publications

References 1 publication

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Infecciones en pacientes reumatológicos asociadas a corticosteroides y antagonistas del factor de necrosis tumoral α

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

Contact Info

Product

Resources

About

Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction

Cited by 203 publications

References 1 publication

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Infecciones en pacientes reumatológicos asociadas a corticosteroides y antagonistas del factor de necrosis tumoral &#945;

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

Contact Info

Product

Resources

About

Infecciones en pacientes reumatológicos asociadas a corticosteroides y antagonistas del factor de necrosis tumoral α